Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P. Treon, Jorge J. Castillo, Antonio Sacco et al.|Journal of Clinical Oncology|2020Cited by 165
<i><scp>MYD</scp>88</i> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P. Treon, Jorge J. Castillo, Joshua Gustine et al.|British Journal of Haematology|2017Cited by 105
<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J. Castillo, Steven P. Treon, Lian Xu et al.|British Journal of Haematology|2019Cited by 103
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanismJiaji G. Chen, Guang Yang, Xia Liu et al.|Blood|2018Cited by 84
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J. Castillo, Steven P. Treon, Kirsten Meid et al.|Leukemia|2021Cited by 82